ATTR Amyloidosis With Cardiomyopathy
Cardiovascular
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Clinical Trials (1)
Total enrollment: 150 patients across 1 trials
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Start: Mar 2026Est. completion: Dec 2026150 patients
N/ANot Yet Recruiting
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr
Physician Program Director, Los Angeles
Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr
J&J MedTech Neurovascular Senior Financial Analyst, R&D
Johnson & Johnson
Irvine, California, United States of America
Yesterday
$79K - $128K/yr
Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90
Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday
Trainee Technical Specialist
Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space